346 related articles for article (PubMed ID: 35165339)
21. Methods Favoring Homology-Directed Repair Choice in Response to CRISPR/Cas9 Induced-Double Strand Breaks.
Yang H; Ren S; Yu S; Pan H; Li T; Ge S; Zhang J; Xia N
Int J Mol Sci; 2020 Sep; 21(18):. PubMed ID: 32899704
[TBL] [Abstract][Full Text] [Related]
22. CRISPR/Cas9-mediated gene knockout is insensitive to target copy number but is dependent on guide RNA potency and Cas9/sgRNA threshold expression level.
Yuen G; Khan FJ; Gao S; Stommel JM; Batchelor E; Wu X; Luo J
Nucleic Acids Res; 2017 Nov; 45(20):12039-12053. PubMed ID: 29036671
[TBL] [Abstract][Full Text] [Related]
23. Scaffold-mediated non-viral delivery platform for CRISPR/Cas9-based genome editing.
Chin JS; Chooi WH; Wang H; Ong W; Leong KW; Chew SY
Acta Biomater; 2019 May; 90():60-70. PubMed ID: 30978509
[TBL] [Abstract][Full Text] [Related]
24. [Effect of MiR-155 Knockout Mediated by Dual sgRNAs on Drug Sensitivity of FLT3-ITD
Wang LY; Jiang PF; Li JZ; Hu JD
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2022 Apr; 30(2):334-340. PubMed ID: 35395959
[TBL] [Abstract][Full Text] [Related]
25. Efficient Multi-Allelic Genome Editing of Primary Cell Cultures via CRISPR-Cas9 Ribonucleoprotein Nucleofection.
Hoellerbauer P; Kufeld M; Paddison PJ
Curr Protoc Stem Cell Biol; 2020 Sep; 54(1):e126. PubMed ID: 32833346
[TBL] [Abstract][Full Text] [Related]
26. Blood-brain barrier-penetrating single CRISPR-Cas9 nanocapsules for effective and safe glioblastoma gene therapy.
Zou Y; Sun X; Yang Q; Zheng M; Shimoni O; Ruan W; Wang Y; Zhang D; Yin J; Huang X; Tao W; Park JB; Liang XJ; Leong KW; Shi B
Sci Adv; 2022 Apr; 8(16):eabm8011. PubMed ID: 35442747
[TBL] [Abstract][Full Text] [Related]
27. HDR-based CRISPR/Cas9-mediated Knockout of PD-L1 in C57BL/6 Mice.
Heeb LV; Taskoparan B; Katsoulas A; Beffinger M; Clavien PA; Kobold S; Gupta A; Berg JV
Bio Protoc; 2023 Jul; 13(14):e4724. PubMed ID: 37497456
[TBL] [Abstract][Full Text] [Related]
28. EGFR-ERK pathway regulates CSN6 to contribute to PD-L1 expression in glioblastoma.
Su L; Guo W; Lou L; Nie S; Zhang Q; Liu Y; Chang Y; Zhang X; Li Y; Shen H
Mol Carcinog; 2020 May; 59(5):520-532. PubMed ID: 32134157
[TBL] [Abstract][Full Text] [Related]
29. Precision genome editing in the CRISPR era.
Salsman J; Dellaire G
Biochem Cell Biol; 2017 Apr; 95(2):187-201. PubMed ID: 28177771
[TBL] [Abstract][Full Text] [Related]
30. MET overexpression contributes to STAT4-PD-L1 signaling activation associated with tumor-associated, macrophages-mediated immunosuppression in primary glioblastomas.
Wang QW; Sun LH; Zhang Y; Wang Z; Zhao Z; Wang ZL; Wang KY; Li GZ; Xu JB; Ren CY; Ma WP; Wang HJ; Li SW; Zhu YJ; Jiang T; Bao ZS
J Immunother Cancer; 2021 Oct; 9(10):. PubMed ID: 34667077
[TBL] [Abstract][Full Text] [Related]
31. Optimizing sgRNA length to improve target specificity and efficiency for the GGTA1 gene using the CRISPR/Cas9 gene editing system.
Matson AW; Hosny N; Swanson ZA; Hering BJ; Burlak C
PLoS One; 2019; 14(12):e0226107. PubMed ID: 31821359
[TBL] [Abstract][Full Text] [Related]
32. A simple and highly efficient method for multi-allelic CRISPR-Cas9 editing in primary cell cultures.
Hoellerbauer P; Kufeld M; Arora S; Wu HJ; Feldman HM; Paddison PJ
Cancer Rep (Hoboken); 2020 Oct; 3(5):e1269. PubMed ID: 32721120
[TBL] [Abstract][Full Text] [Related]
33. Mismatch Intolerance of 5'-Truncated sgRNAs in CRISPR/Cas9 Enables Efficient Microbial Single-Base Genome Editing.
Lee HJ; Kim HJ; Lee SJ
Int J Mol Sci; 2021 Jun; 22(12):. PubMed ID: 34208669
[TBL] [Abstract][Full Text] [Related]
34. HIV-1 Employs Multiple Mechanisms To Resist Cas9/Single Guide RNA Targeting the Viral Primer Binding Site.
Wang Z; Wang W; Cui YC; Pan Q; Zhu W; Gendron P; Guo F; Cen S; Witcher M; Liang C
J Virol; 2018 Oct; 92(20):. PubMed ID: 30068653
[TBL] [Abstract][Full Text] [Related]
35. Brain-targeted CRISPR/Cas9 nanomedicine for effective glioblastoma therapy.
Ruan W; Jiao M; Xu S; Ismail M; Xie X; An Y; Guo H; Qian R; Shi B; Zheng M
J Control Release; 2022 Nov; 351():739-751. PubMed ID: 36174804
[TBL] [Abstract][Full Text] [Related]
36. Glioma-associated mesenchymal stem cells-mediated PD-L1 expression is attenuated by Ad5-Ki67/IL-15 in GBM treatment.
Zhang Q; Zhang J; Wang P; Zhu G; Jin G; Liu F
Stem Cell Res Ther; 2022 Jun; 13(1):284. PubMed ID: 35765095
[TBL] [Abstract][Full Text] [Related]
37. Genome Editing Reveals Glioblastoma Addiction to MicroRNA-10b.
El Fatimy R; Subramanian S; Uhlmann EJ; Krichevsky AM
Mol Ther; 2017 Feb; 25(2):368-378. PubMed ID: 28153089
[TBL] [Abstract][Full Text] [Related]
38. Reversing T Cell Exhaustion by Converting Membrane PD-1 to Its Soluble form in Jurkat Cells; Applying The CRISPR/Cas9 Exon Skipping Strategy.
Yousefi-Najafabadi Z; Mehmandoostli Z; Asgari Y; Kaboli S; Falak R; Kardar GA
Cell J; 2023 Sep; 25(9):633-644. PubMed ID: 37718766
[TBL] [Abstract][Full Text] [Related]
39. Multiple sgRNAs with overlapping sequences enhance CRISPR/Cas9-mediated knock-in efficiency.
Jang DE; Lee JY; Lee JH; Koo OJ; Bae HS; Jung MH; Bae JH; Hwang WS; Chang YJ; Lee YH; Lee HW; Yeom SC
Exp Mol Med; 2018 Apr; 50(4):1-9. PubMed ID: 29622782
[TBL] [Abstract][Full Text] [Related]
40. Sequence features associated with the cleavage efficiency of CRISPR/Cas9 system.
Liu X; Homma A; Sayadi J; Yang S; Ohashi J; Takumi T
Sci Rep; 2016 Jan; 6():19675. PubMed ID: 26813419
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
